Provide Expanded Access to MDV3100 and Monitor Its Safety in Patients With Progressive Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy

NCT01606982 · clinicaltrials.gov ↗

APPROVED_FOR_MARKETING

Status

INDUSTRY

Sponsor class

Conditions

Metastatic Castration-Resistant Prostate Cancer

Interventions

DRUG: MDV3100

Sponsor

Astellas Pharma Global Development, Inc.

Collaborators

[object Object]